2024
51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study
Strober B, Warren R, Gordon K, Langley R, Lebwohl M, Puig L, Tang M, Radic T, Hofmann P, Thoma C, Thaçi D. 51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study. Journal Of The American Academy Of Dermatology 2024, 91: ab87. DOI: 10.1016/j.jaad.2024.07.354.Peer-Reviewed Original ResearchSpesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial
Gottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s409. DOI: 10.25251/skin.8.supp.409.Peer-Reviewed Original ResearchGeneralized pustular psoriasisDermatology Life Quality IndexDermatology Life Quality Index scoresGeneralized pustular psoriasis flaresPustular psoriasisVisits up to weekWeek 4Results Baseline characteristicsLength of diseaseLife Quality IndexLife-threatening diseasePlacebo groupHigh-doseSkin pustulesBaseline characteristicsSpesolimabFlare preventionPlaceboDLQI scoreQuality of lifePatientsWeeksPsoriasisScoresDiseaseSpesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study. Future Rare Diseases 2024, 4: frd57. DOI: 10.2217/frd-2023-0023.Peer-Reviewed Original ResearchGeneralized pustular psoriasisGeneralized pustular psoriasis flaresPustular psoriasisHigh dosesQuality of lifePrevention of flaresCompared to placeboLife-threatening diseasePrevent flaresSpesolimabGPP flaresClinical studiesMedium doseSkin symptomsDoseUnwanted effectsPlaceboPsoriasisSymptomsDrugPustulesWeeksDiseaseMeasuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial
Strober B, Mostaghimi A, Anadkat M, Thoma C, Tang M, Guercio J, Lebwohl M. Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s361. DOI: 10.25251/skin.8.supp.361.Peer-Reviewed Original ResearchGeneralized Pustular Psoriasis Physician Global AssessmentGeneralized pustular psoriasis flaresGeneralized pustular psoriasisPsoriasis Symptom ScalePlacebo-treated patientsVisual analog scalePlacebo groupDermatology Quality of Life IndexPain scoresPustular psoriasisPain visual analog scaleQuality of lifeMajority of patientsPhysician global assessmentDisease burdenLife-threatening skin diseaseQuality of Life Index scoreModerate painSevere painSterile pustulesAcute flaresAnalog scaleDisease activityQuality of Life IndexGPP flaresEffect of High-Dose Subcutaneous Spesolimab on Skin Manifestations: Results from the Pivotal Effisayil 2 Trial of Flare Prevention in Generalized Pustular Psoriasis
Strober B, Augustin M, Tada Y, Garg A, Jullien D, Gottlieb A, Gudjonsson J, Hu N, Hofmann P, Thoma C, Marzano A. Effect of High-Dose Subcutaneous Spesolimab on Skin Manifestations: Results from the Pivotal Effisayil 2 Trial of Flare Prevention in Generalized Pustular Psoriasis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s371. DOI: 10.25251/skin.8.supp.371.Peer-Reviewed Original ResearchGeneralized pustular psoriasisProportion of patientsGeneralized pustular psoriasis flaresWeek 4Pustular psoriasisGeneralized Pustular Psoriasis Physician Global AssessmentPhysician global assessmentTotal scoreLife-threatening skin diseaseRandomized controlled trialsPlacebo groupMaintenance doseLoading doseSterile pustulesSkin manifestationsSpesolimabApproved treatmentPlaceboTreatment periodGlobal assessmentPatientsMonoclonal antibodiesTreatment groupsSkin diseasesBaseline scores
2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. The Lancet 2023, 402: 1541-1551. PMID: 37738999, DOI: 10.1016/s0140-6736(23)01378-8.Peer-Reviewed Original ResearchConceptsPhysician Global Assessment scoreGPP flaresGlobal assessment scoreFlare preventionDose-response relationshipPrimary endpointAssessment scoresPhase 2b trialPustular psoriasis flarePlacebo-controlled trialReceptor monoclonal antibodyEligible study participantsQuality of lifeDose-response curveSubcutaneous placeboPlacebo groupWeek 48Pustular psoriasisPrimary outcomePsoriasis flareTreatment armsPatient groupHypersensitivity reactionsPatient morbiditySpesolimab
2022
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Kotowsky N, Strober B. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 71-78. PMID: 39296823, PMCID: PMC11361522, DOI: 10.1177/24755303221079814.Peer-Reviewed Original ResearchPlaque psoriasisReal-world evidenceMore treatment experiencePsoriasis RegistryPustular psoriasisTreatment experiencePatient-reported outcome measuresGeneralized pustular psoriasisCurrent treatment optionsFuture treatment decisionsQuality of lifeGPP treatmentNeutrophilic pustulesPatient sociodemographicsMedian painMedication useNorth American adultsSystemic diseaseDisease characteristicsTreatment optionsRecurrent flaresDisease burdenPatient outcomesTreatment decisionsOutcome measures
2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line
Strober B, Leman J, Mockenhaupt M, Nakano de Melo J, Nassar A, Prajapati V, Romanelli P, Seneschal J, Tsianakas A, Wei L, Yasuda M, Yu N, Hernandez Daly A, Okubo Y. Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. Dermatology And Therapy 2021, 12: 381-393. PMID: 34904208, PMCID: PMC8850517, DOI: 10.1007/s13555-021-00661-2.Peer-Reviewed Original ResearchClinical practice gapsPustular psoriasisRobust clinical trial dataPractice gapConsistent treatment guidelinesPathogenesis of GPPGeneralized pustular psoriasisInconsistent diagnostic criteriaCare of patientsHealthcare system levelClinical trial dataAppropriate treatment initiationAutoinflammatory skin diseaseUnmet educational needsSterile pustulesTreatment guidelinesTreatment initiationRecurrent flaresGeneral practitionersAutoinflammatory diseasesDiagnostic criteriaPatientsSkin diseasesMore experienceMultidisciplinary team26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry
Strober B, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Lebwohl M. 26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab108. DOI: 10.1016/j.jaad.2021.06.451.Peer-Reviewed Original ResearchUnmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
Strober B, Kotowsky N, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Lebwohl M. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatology And Therapy 2021, 11: 529-541. PMID: 33638115, PMCID: PMC8018987, DOI: 10.1007/s13555-021-00493-0.Peer-Reviewed Original ResearchGPP flaresTreatment optionsPustular psoriasis flareAvailable treatment optionsChronic autoinflammatory diseaseStandard of careUnmet medical needNeutrophilic pustulesSteroid withdrawalPustular psoriasisPsoriasis flareConsensus guidelinesEffective therapyAutoinflammatory diseasesDiagnostic criteriaCurrent unmetConclusionThis surveyMedical needNew flareNatural historyMost dermatologistsDermatologistsTreatmentPustulesLimited information
2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatology And Therapy 2012, 2: 2. PMID: 23205325, PMCID: PMC3510406, DOI: 10.1007/s13555-012-0002-x.Peer-Reviewed Original ResearchSevere psoriasisDifficult treatment scenariosPreferred therapeutic choiceLow-dose methotrexateOptimal treatment optionsCases of psoriasisDelphi consensus approachField of psoriasisErythrodermic psoriasisPalmoplantar psoriasisPustular psoriasisTopical therapySuch patientsTreatment optionsPsoriasis casesTherapeutic choiceClinical trialsConsensus panelPsoriasisScant dataDelphi exerciseLive meetingsPatientsTherapyExercise